Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Core Viewpoint - Virax Biolabs Group Limited has successfully closed a registered direct offering, raising approximately $5 million through the sale of 1,108,892 ordinary shares at a price of $4.50 per share [1][2]. Company Overview - Virax Biolabs Group Limited is a biotechnology company focused on detecting immune responses and diagnosing viral diseases [5]. - The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, which is particularly effective for diagnosing post-viral syndromes like Long COVID and other chronic conditions related to immune dysregulation [5]. Offering Details - The offering was facilitated by H.C. Wainwright & Co. as the exclusive placement agent [1]. - The gross proceeds from the offering were approximately $5 million before deducting fees and expenses [2]. - The shares were sold under a "shelf" registration statement filed with the SEC, which was declared effective in December 2023 [3].